Reportedly receiving the first Current Procedural Terminology (CPT) III code from the American Medical Association (AMA) for artificial intelligence (AI)-enabled brain magnetic resonance imaging (MRI) software, Icometrix says its adjunctive quantification software can be utilized for diagnosis and assessment of conditions ranging from Alzheimer’s disease and epilepsy to stroke and dementia.
Creating a potential path for reimbursement, the American Medical Association (AMA) has issued a Current Procedural Terminology (CPT) III code for the use of icometrix’s artificial intelligence (AI)-powered brain magnetic resonance imaging (MRI) quantification software.
Icometrix, which has five Food and Drug Administration (FDA)-cleared AI software applications for brain MRI and computed tomography (CT), said the CPT III code is the first one issued for adjunctive AI quantification of brain MRI scans.
“Precision medicine is vital for improving treatment of neurological conditions, and especially for multiple sclerosis,” noted Tim Coetzee, PhD, the chief advocacy, services, and science officer at the National Multiple Sclerosis Society. “This recognition creates a path for icometrix’s innovative technology to be integrated into the management of multiple sclerosis (MS) and takes us one step closer to a future where precision medicine guides treatment decisions.”
Icobrain ms, one of the aforementioned AI software applications, facilitates objective quantification and tracking of white matter hyperintensities on FLAIR, TI MRI and contrast-enhanced T1 MRI, according to icometrix. The company added that its portfolio of AI-enabled neuroimaging software can be utilized in the diagnosis and assessment of treatment for conditions ranging from Alzheimer’s disease and MS to stroke and epilepsy.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
The Reading Room Podcast: A Closer Look at Remote MRI Safety, Part 2
July 25th 2025In the second of a multi-part podcast episode, Emanuel Kanal, M.D. and Tobias Gilk, MRSO, MRSE, share their perspectives on remote MRI safety protocols for ensuring screening accuracy and adherence to conditional implant guidelines as well as a rapid and effective response to adverse events.
The Reading Room Podcast: Current and Emerging Insights on Abbreviated Breast MRI, Part 2
July 23rd 2025In the second part of a multi-part podcast episode, Stamatia Destounis, MD, Emily Conant, MD and Habib Rahbar, MD, discuss key sequences for abbreviated breast MRI and how it stacks up to other breast cancer screening modalities.
FDA Clears Point-Of-Care Ultrasound Platform and AI Software for Neuraxial Procedures
July 17th 2025The dual FDA clearances for the Accuro 3S point-of-care ultrasound device and the SpineNav-AI machine learning-based software may enhance precision and safety with ultrasound-guided neuraxial procedures.